The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review

In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation

(2023) Björn-Erik Ole Jensen et al.   NATURE MEDICINE

The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy

(2023) Henrieke A. B. Prins et al.   Science Advances

Impact of Tamoxifen on Vorinostat-Induced HIV Expression in Women on Antiretroviral Therapy (ACTG A5366:The MOXIE trial)

(2022) Eileen P Scully et al.   CLINICAL INFECTIOUS DISEASES

Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial

(2022) Jeffrey S. Miller et al.   NATURE MEDICINE

Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy

(2022) Thomas S. Uldrick et al.   Science Translational Medicine

Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial

(2022) Henning Gruell et al.   Lancet Microbe

Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial

(2022) Jesper D. Gunst et al.   NATURE MEDICINE

SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8+ T-cells

(2022) Eva M. Stevenson et al.   Nature Communications

Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in people living with HIV with cancer on antiretroviral therapy: The AIDS Malignancy Consortium-095 study

(2021) Thomas A Rasmussen et al.   CLINICAL INFECTIOUS DISEASES

The impact of immune checkpoint therapy on the latent reservoir in HIV infected individuals with cancer on antiretroviral therapy

(2021) Jillian S.Y. Lau et al.   AIDS

Shocking HIV-1 with immunomodulatory latency reversing agents

(2021) Anna Kula-Pacurar et al.   SEMINARS IN IMMUNOLOGY

PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews

(2021) Matthew J Page et al.   BMJ-British Medical Journal

Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal

(2021) James H. McMahon et al.   AIDS

Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat

(2021) Cynthia L Gay et al.   JOURNAL OF INFECTIOUS DISEASES

The Current Status of Latency Reversing Agents for HIV-1 Remission

(2021) Anthony Rodari et al.   Annual Review of Virology

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

(2020) Sarah Fidler et al.   LANCET

Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline

(2020) Mhairi Campbell et al.   BMJ-British Medical Journal

Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection

(2020) Cynthia L. Gay et al.   Scientific Reports

HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)

(2020) Beatriz Mothe et al.   Frontiers in Immunology

Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessments

(2020) Luke A. McGuinness et al.   Research Synthesis Methods

Vesatolimod, a toll-like receptor 7 agonist, induces immune activation in virally suppressed adults with HIV-1

(2020) Sharon A Riddler et al.   CLINICAL INFECTIOUS DISEASES

The histone deacetylase inhibitor chidamide induces intermittent viraemia in HIV‐infected patients on suppressive antiretroviral therapy

(2020) JH Li et al.   HIV MEDICINE

A phase I/II randomized, placebo-controlled trial of romidepsin in persons with HIV-1 on suppressive antiretroviral therapy to assess safety and activation of HIV-1 expression (A5315)

(2020) Deborah K McMahon et al.   JOURNAL OF INFECTIOUS DISEASES

Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound

(2020) María Rosa López-Huertas et al.   Scientific Reports

HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation

(2019) Ravindra K. Gupta et al.   NATURE

Effects of 24 Week Toll-Like Receptor 9 Agonist Treatment in HIV-1+ Individuals

(2019) Line K. Vibholm et al.   AIDS

HIV “shock and kill” therapy: In need of revision

(2019) Erik Abner et al.   ANTIVIRAL RESEARCH

Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial

(2019) Mansi Saxena et al.   Frontiers in Immunology

RoB 2: a revised tool for assessing risk of bias in randomised trials

(2019) Jonathan A C Sterne et al.   BMJ-British Medical Journal

A broad drug arsenal to attack a strenuous latent HIV reservoir

(2019) Mateusz Stoszko et al.   Current Opinion in Virology

Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4+ T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy

(2018) Nadia Madrid-Elena et al.   JOURNAL OF VIROLOGY

Influenza Vaccination Can Broadly Activate the HIV Reservoir During Antiretroviral Therapy

(2018) Aaron Christensen-Quick et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency

(2017) Nancie M. Archin et al.   JOURNAL OF CLINICAL INVESTIGATION

Standard vaccines increase HIV-1 transcription during antiretroviral therapy

(2016) Christina Yek et al.   AIDS

Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA

(2016) Christine Katlama et al.   AIDS

Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy

(2016) Carolina Gutiérrez et al.   AIDS

A Systematic Review of the Inclusion (or Exclusion) of Women in HIV Research

(2016) Mirjam J. Curno et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

(2016) Jonathan AC Sterne et al.   BMJ-British Medical Journal

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

(2016) Jonathan AC Sterne et al.   BMJ-British Medical Journal

Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial

(2016) Steffen Leth et al.   Lancet HIV

Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma

(2015) Fiona Wightman et al.   AIDS

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

(2015) Ole S. Søgaard et al.   PLoS Pathogens

Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial

(2015) Chad J Achenbach et al.   Lancet HIV

Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study

(2015) Julian H Elliott et al.   Lancet HIV

HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat

(2014) N. M. Archin et al.   JOURNAL OF INFECTIOUS DISEASES

Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial

(2014) Alain Lafeuillade et al.   AIDS Research and Therapy

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

(2014) Thomas A Rasmussen et al.   Lancet HIV

A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy

(2013) A. M. Spivak et al.   CLINICAL INFECTIOUS DISEASES

Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study

(2012) JP Routy et al.   HIV MEDICINE

Redefining the Viral Reservoirs that Prevent HIV-1 Eradication

(2012) Evelyn Eisele et al.   IMMUNITY

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

(2012) N. M. Archin et al.   NATURE

Shock and kill

(2012) Steven G. Deeks   NATURE

Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection

(2010) Nancie M. Archin et al.   PLoS One

Long-Term Control of HIV byCCR5Delta32/Delta32 Stem-Cell Transplantation

(2009) Gero Hütter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells

(2008) Nancy M Archin et al.   AIDS